25 May 2022

Company Announcements Office
Australian Securities Exchange

Vectus Announces Completion of Final Single Ascending Dose Study and First Multiple Ascending Dose Study for VB0004

- **Completion of S.A.D. Phase I study with no adverse events observed**
- **Successful outcome for first M.A.D. cohort**
- **Interim PK data points to potential for single daily dose of VB0004 to treat various chronic conditions**

Vectus Biosystems Limited (ASX:VBS, Vectus or the Company) is pleased to announce that all five of the planned cohorts in the Single Ascending Dose (S.A.D.) segment of its first-in-human trial: "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk", have been reviewed by the Trial Safety Review Committee (Committee). The results of the 2mg, 10mg, 30mg, 100mg and 300mg doses of VB0004 have now been reviewed by the Committee. Of greatest significance, no adverse events have been observed at any of the five doses of VB0004 studied to-date. Further, the latest dose of 300mg has added very significantly to the therapeutic safety margin for VB0004.

The interim pharmacokinetic (PK) analysis confirmed that the time to achieve its maximal concentration (T_{max}) after dosing occurred at six to eight hours and the plasma half-life (the time taken for the plasma concentration of VB0004 to decrease by 50%) was 17 to 17.5 hours. This preliminary data provides further evidence that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis.

The Committee also reviewed the outcomes for the first Multiple Ascending Dose (M.A.D.) cohort in which 10mg of VB0004 was administered daily for 14 days. Again, there were no adverse events adding to the impressive safety profile of VB0004.

The Committee has now given permission for the second M.A.D. cohort to proceed and the first three participants have been enrolled.

The Company's Chairman, Dr Ron Shnier, said: "This is an exciting development in Vectus' journey of validating an orally-dosable anti-fibrotic, which could not just slow down disease progression, but in fact, potentially provide clinical reversal of existing damage in a truly transformational agent."

The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov), and has been provided with the identifier NCT04925050. Protocol details may be found using this number on the ClinicalTrials.gov public website.

This announcement was authorised by the Vectus Board of Directors.

For more information:

Karen Duggan
Chief Executive Officer and Executive Director

Matthew Wright
NWR Communications
P: 0451 896 420
E: matt@nwrcommunications.com.au

About Vectus Biosystems Limited

Vectus Biosystems Limited is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising A$5.1 million. Funds from the IPO were predominantly used to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following successful results, the late 2019 convertible note fundraising and the late 2020 share placement, the Company has funding for its Human Phase I trial. Vectus' strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.

The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus' wholly-owned subsidiary, Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems. The Company's current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.